The endocannabinoid system: a potential target for the treatment of various diseases

H Lowe, N Toyang, B Steele, J Bryant… - International journal of …, 2021 - mdpi.com
The Endocannabinoid System (ECS) is primarily responsible for maintaining homeostasis, a
balance in internal environment (temperature, mood, and immune system) and energy input …

Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies

DP Finn, S Haroutounian, AG Hohmann, E Krane… - Pain, 2021 - journals.lww.com
This narrative review represents an output from the International Association for the Study of
Pain's global task force on the use of cannabis, cannabinoids, and cannabis-based …

Trends in use, pharmacology, and clinical applications of emerging herbal nutraceuticals

EM Williamson, X Liu, AA Izzo - British Journal of …, 2020 - Wiley Online Library
The nutraceuticals market is vast, encompassing many different products with inconsistent
levels of evidence available to support their use. This overview represents a Western …

[HTML][HTML] Cortical GABAergic dysfunction in stress and depression: new insights for therapeutic interventions

MV Fogaça, RS Duman - Frontiers in cellular neuroscience, 2019 - frontiersin.org
Major depressive disorder (MDD) is a debilitating illness characterized by neuroanatomical
and functional alterations in limbic structures, notably the prefrontal cortex (PFC), that can be …

Cannabidiol for pain treatment: focus on pharmacology and mechanism of action

J Mlost, M Bryk, K Starowicz - International journal of molecular sciences, 2020 - mdpi.com
Cannabis has a long history of medical use. Although there are many cannabinoids present
in cannabis, Δ9tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) are the two …

The “entourage effect”: terpenes coupled with cannabinoids for the treatment of mood disorders and anxiety disorders

SG Ferber, D Namdar, D Hen-Shoval… - Current …, 2020 - ingentaconnect.com
Mood disorders are the most prevalent mental conditions encountered in psychiatric
practice. Numerous patients suffering from mood disorders present with treatment-resistant …

[HTML][HTML] Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders

SB Sartori, N Singewald - Pharmacology & therapeutics, 2019 - Elsevier
Current medication for anxiety disorders is suboptimal in terms of efficiency and tolerability,
highlighting the need for improved drug treatments. In this review an overview of drugs …

Cannabidiol (CBD) use in psychiatric disorders: A systematic review

S Bonaccorso, A Ricciardi, C Zangani, S Chiappini… - Neurotoxicology, 2019 - Elsevier
Abstract Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) are the most represented
phytocannabinoids in Cannabis sativa plants. However, CBD may present with a different …

Cannabis and mental illness: a review

DJE Lowe, JD Sasiadek, AS Coles… - European archives of …, 2019 - Springer
With the increasing push to legalize cannabis in Western nations, there is a need to gage
the potential impact of this policy change on vulnerable populations, such as those with …

Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study

A Capano, R Weaver, E Burkman - Postgraduate medicine, 2020 - Taylor & Francis
Context: Chronic pain is highly prevalent in most of the industrialized nations around the
world. Despite the documented adverse effects, opioids are widely used for pain …